NUVB vs. URGN
Compare and contrast key facts about Nuvation Bio Inc. (NUVB) and UroGen Pharma Ltd. (URGN).
Performance
NUVB vs. URGN - Performance Comparison
Loading graphics...
NUVB vs. URGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
NUVB Nuvation Bio Inc. | -49.67% | 236.84% | 76.16% | -21.35% | -77.41% | -27.35% | 17.00% |
URGN UroGen Pharma Ltd. | -19.13% | 119.91% | -29.00% | 69.11% | -6.73% | -47.23% | -21.48% |
Fundamentals
NUVB:
$1.55B
URGN:
$932.42M
NUVB:
-$0.60
URGN:
-$3.18
NUVB:
24.56
URGN:
8.34
NUVB:
$62.90M
URGN:
$109.79M
NUVB:
$54.46M
URGN:
$97.34M
NUVB:
-$199.90M
URGN:
-$127.69M
Returns By Period
In the year-to-date period, NUVB achieves a -49.67% return, which is significantly lower than URGN's -19.13% return.
NUVB
- 1D
- 5.13%
- 1M
- -22.77%
- YTD
- -49.67%
- 6M
- 21.89%
- 1Y
- 157.71%
- 3Y*
- 39.54%
- 5Y*
- -15.06%
- 10Y*
- —
URGN
- 1D
- 5.34%
- 1M
- -0.42%
- YTD
- -19.13%
- 6M
- 6.31%
- 1Y
- 78.17%
- 3Y*
- 27.03%
- 5Y*
- -0.71%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NUVB vs. URGN — Risk / Return Rank
NUVB
URGN
NUVB vs. URGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Nuvation Bio Inc. (NUVB) and UroGen Pharma Ltd. (URGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NUVB | URGN | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.67 | 0.69 | +0.98 |
Sortino ratioReturn per unit of downside risk | 2.46 | 1.78 | +0.68 |
Omega ratioGain probability vs. loss probability | 1.34 | 1.27 | +0.07 |
Calmar ratioReturn relative to maximum drawdown | 2.72 | 1.08 | +1.64 |
Martin ratioReturn relative to average drawdown | 6.64 | 3.00 | +3.65 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| NUVB | URGN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.67 | 0.69 | +0.98 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.20 | -0.01 | -0.19 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.18 | 0.04 | -0.22 |
Correlation
The correlation between NUVB and URGN is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
NUVB vs. URGN - Dividend Comparison
Neither NUVB nor URGN has paid dividends to shareholders.
Drawdowns
NUVB vs. URGN - Drawdown Comparison
The maximum NUVB drawdown since its inception was -93.39%, roughly equal to the maximum URGN drawdown of -93.98%. Use the drawdown chart below to compare losses from any high point for NUVB and URGN.
Loading graphics...
Drawdown Indicators
| NUVB | URGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.39% | -93.98% | +0.59% |
Max Drawdown (1Y)Largest decline over 1 year | -57.55% | -66.24% | +8.69% |
Max Drawdown (5Y)Largest decline over 5 years | -93.35% | -82.64% | -10.71% |
Current DrawdownCurrent decline from peak | -69.05% | -71.01% | +1.96% |
Average DrawdownAverage peak-to-trough decline | -65.43% | -61.55% | -3.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.53% | 23.79% | -0.26% |
Volatility
NUVB vs. URGN - Volatility Comparison
Nuvation Bio Inc. (NUVB) has a higher volatility of 16.34% compared to UroGen Pharma Ltd. (URGN) at 15.35%. This indicates that NUVB's price experiences larger fluctuations and is considered to be riskier than URGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| NUVB | URGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.34% | 15.35% | +0.99% |
Volatility (6M)Calculated over the trailing 6-month period | 69.18% | 49.37% | +19.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 95.04% | 113.74% | -18.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 76.00% | 91.48% | -15.48% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 73.56% | 79.73% | -6.17% |
Financials
NUVB vs. URGN - Financials Comparison
This section allows you to compare key financial metrics between Nuvation Bio Inc. and UroGen Pharma Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NUVB vs. URGN - Profitability Comparison
NUVB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Nuvation Bio Inc. reported a gross profit of 41.44M and revenue of 41.87M. Therefore, the gross margin over that period was 99.0%.
URGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, UroGen Pharma Ltd. reported a gross profit of 34.55M and revenue of 37.84M. Therefore, the gross margin over that period was 91.3%.
NUVB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Nuvation Bio Inc. reported an operating income of -34.04M and revenue of 41.87M, resulting in an operating margin of -81.3%.
URGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, UroGen Pharma Ltd. reported an operating income of -19.12M and revenue of 37.84M, resulting in an operating margin of -50.5%.
NUVB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Nuvation Bio Inc. reported a net income of -36.59M and revenue of 41.87M, resulting in a net margin of -87.4%.
URGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, UroGen Pharma Ltd. reported a net income of -26.36M and revenue of 37.84M, resulting in a net margin of -69.7%.